Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMI-358 in Distal Subungual Onychomycosis
NCT01093118Phase 2Terminated
- Sponsor
- Talima Therapeutics
- Start
- Sep 2009
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TMI-358 in distal subungual onychomycosis (DSO), sponsored by Talima Therapeutics. Started Sep 2009; status: terminated.
02
Drugs
TMI-358
03
Conditions
distal subungual onychomycosis (DSO)
Beyond the preview
Go deeper on NCT01093118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01093118.